Bimekizumab for Plaque Psoriasis

(BE TOGETHER Trial)

Recruiting at 56 trial locations

Overseen By UCB Cares

Age: < 18

Sex: Any

Trial Phase: Phase 3

Sponsor: UCB Biopharma SRL

Must not be taking: IL-17 biologics

Disqualifiers: Inflammatory bowel disease, Active infection, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 2 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

168 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called bimekizumab for children and teens with moderate to severe plaque psoriasis, a skin condition that causes red, scaly patches. Researchers aim to determine if bimekizumab, an experimental treatment, is more effective than the existing treatment, ustekinumab. Participants will be randomly assigned to receive either bimekizumab or ustekinumab to compare the effectiveness of these treatments. Children and teens who have had plaque psoriasis for at least three months and have significant skin involvement, such as patches covering a large part of their body, might be suitable for the trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially bringing a new treatment to market.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications, but it mentions that participants should not have received certain drugs outside specified timeframes. It's best to discuss your current medications with the trial team to see if they are allowed.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that bimekizumab has been tested for safety in treating plaque psoriasis. Studies found that nearly two-thirds of patients using bimekizumab achieved clear skin and maintained it for up to four years. The safety results remained consistent across these studies, indicating that bimekizumab was generally well-tolerated over time.

Although some side effects were reported, the treatment's safety has been deemed sufficient to warrant further research. As this study is in an advanced phase, it strongly suggests that earlier trials found bimekizumab safe, particularly for psoriasis. For more questions or concerns, consult your healthcare provider. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for psoriasis?

Researchers are excited about bimekizumab for plaque psoriasis because it targets both interleukin-17A and interleukin-17F, which are proteins involved in inflammation. This dual mechanism is different from current treatments like ustekinumab and secukinumab, which generally target only one interleukin. By blocking both, bimekizumab has the potential to provide more comprehensive control of the inflammatory process. This could lead to better skin clearance and longer-lasting results for patients.

What evidence suggests that bimekizumab might be an effective treatment for plaque psoriasis?

Research has shown that bimekizumab, one of the treatments in this trial, effectively treats moderate to severe plaque psoriasis. Studies have found that nearly two-thirds of patients achieve completely clear skin and maintain it for up to four years. Another study found that this treatment improves skin areas affecting daily life. The treatment has been linked to long-term skin improvements and is generally considered safe. These findings suggest that bimekizumab could be a promising option for managing psoriasis symptoms over the long term. Participants in this trial may receive either bimekizumab or the active comparator, ustekinumab, to evaluate their effectiveness and safety. ^{1 2 3 6 7}

Who Is on the Research Team?

UCB Cares

Principal Investigator

001 844 599 2273

Are You a Good Fit for This Trial?

This trial is for children and adolescents aged 6 to less than 18 with moderate to severe plaque psoriasis. They must have a body surface area affected by psoriasis of at least 10%, an IGA score of ≥3, weigh over 15 kg, and be eligible for systemic therapy or photo/chemotherapy.

Inclusion Criteria

I am between 6 and 17 years old and can legally consent to participate.

Over 10% of my body is affected by psoriasis.

My psoriasis is severe, affecting my face, genitals, or hands and feet.

Exclusion Criteria

I am currently experiencing thoughts of harming myself or have attempted suicide.

I have not been diagnosed with severe depression in the last 6 months.

I did not respond to IL-17 treatment or have tried multiple other biologics.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Initial Treatment

Participants receive either bimekizumab or ustekinumab during the Initial Treatment Period

16 weeks

Maintenance

Participants continue with bimekizumab or ustekinumab, with possible switch to bimekizumab regimen 2

32 weeks

Open-label Extension (OLE)

Participants may opt to continue receiving bimekizumab in an open-label extension

104 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

20 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Bimekizumab
• Ustekinumab

Trial Overview

The study compares the effectiveness and safety of Bimekizumab versus Ustekinumab in treating plaque psoriasis. Both drugs are given as injections under the skin (subcutaneously), with participants randomly assigned to receive one or the other.

How Is the Trial Designed?

Group I: bimekizumab Experimental Treatment 2 Interventions

Study participants randomized to this arm receive bimekizumab dosage regimen 1 at pre-specified timepoints during the Initial Treatment Period (16 weeks). They continue to receive bimekizumab dosage regimen 2 in the Maintenance Period (32 weeks). Under certain conditions study participants may be offered to continue on bimekizumab dosage regimen 2 in the Open-label Extension (OLE) Period (104 weeks).

Group II: ustekinumab Active Control 3 Interventions

Study participants randomized to this arm receive ustekinumab at pre-specified timepoints during the Initial Treatment Period (16 weeks) and during the Maintenance Period. Under certain conditions participants may switch to bimekizumab dosage regimen 1 (16 weeks) and continue with bimekizumab dosage regimen 2 in the last 16 weeks of the Maintenance Period. Under certain conditions study participants may be offered to participate in the OLE Period also receiving bimekizumab dosage regimen 2.

Bimekizumab is already approved in European Union, United States for the following indications:

Approved in European Union as Bimzelx for:

• Moderate to severe plaque psoriasis
• Active psoriatic arthritis
• Non-radiographic axial spondyloarthritis
• Active ankylosing spondylitis

Approved in United States as Bimzelx for:

• Moderate-to-severe plaque psoriasis
• Active psoriatic arthritis
• Non-radiographic axial spondyloarthritis
• Active ankylosing spondylitis
• Hidradenitis suppurativa

Who Is Running the Clinical Trial?

UCB Biopharma SRL

Lead Sponsor

Trials

118

Recruited

23,200+

Jean-Christophe Tellier

UCB Biopharma SRL

Chief Executive Officer since 2015

MD from University of Reims Champagne-Ardenne, Rheumatology specialization from University of Paris V, Executive business programs at Harvard and INSEAD

Dr. Iris Loew-Friedrich

UCB Biopharma SRL

Chief Medical Officer since 2014

MD from University of Leuven, PhD in Medical Sciences from University of Leuven

Published Research Related to This Trial

In a phase 3 trial involving 435 patients with moderate to severe plaque psoriasis, bimekizumab demonstrated significant efficacy, with 91% of patients achieving a 90% improvement in psoriasis severity (PASI90) at week 16 compared to only 1% in the placebo group.

Bimekizumab was well tolerated over 56 weeks, with no unexpected safety issues, and maintained high response rates with both every 4-week and every 8-week dosing schedules.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Gordon, KB., Foley, P., Krueger, JG., et al.[2021]

Bimekizumab, a monoclonal antibody targeting IL-17A and IL-17F, showed significant efficacy in treating moderate-to-severe plaque psoriasis, with 57% of patients achieving complete skin clearance (PASI 100) by week 12 after treatment.

The treatment led to rapid normalization of skin-related gene expressions associated with psoriasis, indicating a profound biological response, which supports further investigation of maintenance dosing every 4 or 8 weeks in future studies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Oliver, R., Krueger, JG., Glatt, S., et al.[2022]

Bimekizumab, a new monoclonal antibody that targets IL-17A and IL-17F, has been shown to be effective in treating moderate to severe plaque psoriasis, achieving significant improvements (PASI90 and PASI100) as early as week 4 and maintaining these results for up to 52 weeks.

In Phase III clinical trials, bimekizumab demonstrated a faster onset of action and greater efficacy compared to other treatments like adalimumab, ustekinumab, and secukinumab, while maintaining a comparable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge. Ruggiero, A., Potestio, L., Camela, E., et al.[2022]

Bimekizumab is significantly more effective than placebo and active comparators in treating moderate-to-severe plaque psoriasis, showing rapid onset of action with clinically meaningful responses observed as early as 4 weeks after the first dose.

The safety profile of bimekizumab is comparable to that of active comparators, with similar rates of adverse events, although oral candidiasis was noted as a common side effect.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials. Wang, Y., Li, S., Bai, J., et al.[2023]

Bimekizumab demonstrated superior efficacy compared to secukinumab in achieving complete skin clearance (PASI 100) in patients with moderate to severe plaque psoriasis, with 74.8% of patients achieving this at Week 48 compared to 52.8% for secukinumab.

The high rates of skin clearance achieved with bimekizumab were maintained through Week 96, and patients switching from secukinumab to bimekizumab also experienced significant improvements, indicating its effectiveness over a 2-year period.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. Strober, B., Paul, C., Blauvelt, A., et al.[2023]

In a study involving 6892 adult patients with moderate-to-severe psoriasis, ixekizumab demonstrated a long-term safety profile with low incidence rates of serious adverse events (5.4 per 100 patient-years) and serious infections (1.3 per 100 patient-years) over a cumulative exposure of 18,025.7 patient-years.

No new or unexpected safety events were reported, with the incidence rates for major adverse cerebro-cardiovascular events and inflammatory bowel disease remaining low, indicating that ixekizumab is a safe treatment option for psoriasis over extended periods.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure. Griffiths, CEM., Gooderham, M., Colombel, JF., et al.[2022]

In a 52-week phase 3 study involving 108 Japanese patients with moderate-to-severe plaque psoriasis, bimekizumab treatment led to significantly better clinical outcomes compared to both ustekinumab and placebo, with 85.5% of patients achieving a PASI 90 response at week 16.

Bimekizumab was well-tolerated in the Japanese population, showing a safety profile consistent with that observed in the global study, indicating its potential as an effective treatment option for psoriasis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study. Asahina, A., Okubo, Y., Morita, A., et al.[2023]

Bimekizumab is a novel therapeutic agent that targets and neutralizes both IL-17A and IL-17F cytokines, which are involved in the inflammatory processes of plaque psoriasis and psoriatic arthritis.

This review highlights the unique molecular structure of bimekizumab compared to other bispecific agents, suggesting it may offer a more effective treatment option for patients with psoriasis and related conditions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential. Chiricozzi, A., De Simone, C., Fossati, B., et al.[2020]

Bimekizumab (BKZ) demonstrated sustained efficacy in treating active psoriatic arthritis (PsA) from Week 16 to Week 52, maintaining significant improvements in ACR response criteria and psoriasis severity measures.

The treatment was well tolerated, with a similar rate of treatment-emergent adverse events (TEAEs) compared to adalimumab, and no new safety concerns were identified, although localized Candida infections were noted in a small percentage of patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Ritchlin, CT., Coates, LC., McInnes, IB., et al.[2023]

In a phase 3 trial involving 567 patients with moderate to severe plaque psoriasis, bimekizumab demonstrated significantly higher efficacy than both ustekinumab and placebo, with 85% of patients achieving a 90% improvement in psoriasis severity (PASI90) at week 16.

The safety profile of bimekizumab was consistent with previous studies, with serious treatment-emergent adverse events reported in 6% of patients, indicating it is a safe option for treating psoriasis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Reich, K., Papp, KA., Blauvelt, A., et al.[2021]

Citations

1.

ucb.com

ucb.com/newsroom/press-releases/article/bimzelxr-bimekizumab-bkzx-five-year-data-at-aad-2025-showed-sustained-skin-clearance-and-long-term-efficacy-in-moderate-to-severe-plaque-psoriasis

BIMZELX[®] (bimekizumab-bkzx) five-year data at AAD ...

Bimekizumab treatment resulted in sustained improvements in pain and fatigue in patients with active psoriatic arthritis and baseline psoriasis: 2-year results ...

2.

ucb-usa.com

ucb-usa.com/stories-media/UCB-U-S-News/detail/article/bimzelxr-bimekizumab-bkzx-data-moderate-severe-plaque-psoriasis-at-eadv-showed-complete-skin-clearance-sustained-over-four-years

BIMZELX® (bimekizumab-bkzx) Data in Moderate-to- ...

BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years.

3.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/40286813/

Results from the BE BRIGHT open-label extension trial

Almost two-thirds of bimekizumab-treated patients achieved and maintained complete skin clearance through 4 years, making bimekizumab an effective, rapid, and ...

4.

jaad.org

jaad.org/article/S0190-9622(25)00668-1/fulltext

Bimekizumab durability of efficacy through 196 weeks and ...

Almost two-thirds of bimekizumab-treated patients achieved and maintained complete skin clearance through 196 weeks, and safety data were ...

5.

ucbcompass.com

ucbcompass.com/sites/default/files/2024-10/EADV24_4-Year%20HIA_submitted.pdf

Bimekizumab 4-year efficacy in high-impact areas in ...

These results demonstrate that bimekizumab can provide high-level and durable improvement in psoriasis in areas which significantly impact daily functioning and ...

6.

academic.oup.com

academic.oup.com/bjd/article/193/1/44/7979209

Bimekizumab efficacy and safety through 3 years in patients ...

Two-thirds of patients maintained clear skin over 3 years. Patients who switched from secukinumab to bimekizumab had similar results to those ...

7.

sciencedirect.com

sciencedirect.com/science/article/pii/S0190962225006681

Bimekizumab durability of efficacy through 196 weeks and ...

Almost two-thirds of bimekizumab-treated patients achieved and maintained complete skin clearance through 196 weeks, and safety data were consistent with ...